Fig. 5.

JHU-083 attenuates CSDS-induced increase in glutaminase activity in CD11b⁺ cells in the prefrontal cortex and hippocampus, but not in the cerebellum. a–c CSDS induced significant elevation in ex vivo glutaminase activity specifically in CD11b⁺ cells in the prefrontal cortex (PFC) and hippocampus (HPC), but not in the cerebellum, that was completely normalized by JHU-083 administration (1.82 mg/kg, p.o., q.o.d.). There was no effect of JHU-083 on glutaminase activity in CD11b⁺ cells harvested from the prefrontal cortex in control mice, whereas down-regulated effect in the hippocampus in control mice (Ctr). d–f There was no effect of CSDS or JHU-083 treatment on glutaminase activity in non-CD11b⁺ cells in the prefrontal cortex and hippocampus. Expression of glutaminase was slightly increased in the cerebellum by CSDS. Bars represent means of each group in three independent experiments. Ctr + Vehicle vs CSDS + Vehicle: **p < 0.01; CSDS + Vehicle vs CSDS + JHU-083: ^##p < 0.01, comparison between groups by two-way ANOVA with Tukey’s post-hoc test. Data are presented as the mean ± SEM